1-1	0-16	Interhemispheric	_	_
1-2	17-29	connectivity	_	_
1-3	30-33	and	_	_
1-4	34-45	hemispheric	_	_
1-5	46-60	specialization	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-6	61-63	in	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-7	64-77	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	_
1-8	78-86	patients	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-9	87-90	and	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-10	91-96	their	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-11	97-107	unaffected	_	_
1-12	108-116	siblings	_	_
1-13	117-128	Hemispheric	_	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-14	129-140	integration	_	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-15	141-144	and	_	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-16	145-159	specialization	_	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-17	160-163	are	_	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-18	164-167	two	_	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-19	168-177	prominent	_	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
1-20	178-192	organizational	_	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
1-21	193-203	principles	_	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
1-22	204-207	for	_	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
1-23	208-219	macroscopic	_	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
1-24	220-225	brain	_	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
1-25	226-234	function	_	_
1-26	234-235	.	_	_

2-1	236-247	Impairments	_	_
2-2	248-250	of	_	_
2-3	251-267	interhemispheric	_	_
2-4	268-279	cooperation	_	_
2-5	280-284	have	_	_
2-6	285-289	been	_	_
2-7	290-298	reported	_	_
2-8	299-301	in	_	_
2-9	302-315	schizophrenia	_	_
2-10	316-324	patients	_	_
2-11	324-325	,	_	_
2-12	326-329	but	_	_
2-13	330-337	whether	_	_
2-14	338-342	such	_	_
2-15	343-356	abnormalities	_	_
2-16	357-363	should	_	_
2-17	364-366	be	_	_
2-18	367-377	attributed	_	_
2-19	378-380	to	_	_
2-20	381-388	effects	_	_
2-21	389-391	of	_	_
2-22	392-399	illness	_	_
2-23	400-402	or	_	_
2-24	403-411	familial	_	_
2-25	412-416	risk	_	_
2-26	417-424	remains	_	_
2-27	425-437	inconclusive	_	_
2-28	437-438	.	_	_

3-1	439-447	Moreover	_	_
3-2	447-448	,	_	_
3-3	449-451	it	_	_
3-4	452-454	is	_	_
3-5	455-462	unclear	_	_
3-6	463-466	how	_	_
3-7	467-480	abnormalities	_	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
3-8	481-483	in	_	_
3-9	484-500	interhemispheric	_	_
3-10	501-513	connectivity	_	_
3-11	514-520	impact	_	_
3-12	521-532	hemispheric	_	_
3-13	533-547	specialization	_	_
3-14	547-548	.	_	_

4-1	549-551	To	_	_
4-2	552-559	address	_	_
4-3	560-565	these	_	_
4-4	566-575	questions	_	_
4-5	575-576	,	_	_
4-6	577-579	we	_	_
4-7	580-589	performed	_	_
4-8	590-598	magnetic	_	_
4-9	599-608	resonance	_	_
4-10	609-616	imaging	_	_
4-11	617-618	(	_	_
4-12	618-621	MRI	_	_
4-13	621-622	)	_	_
4-14	623-625	in	_	_
4-15	626-627	a	_	_
4-16	628-633	large	_	_
4-17	634-640	cohort	_	_
4-18	641-643	of	_	_
4-19	644-647	253	_	_
4-20	648-660	participants	_	_
4-21	660-661	,	_	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
4-22	662-671	including	_	_
4-23	672-674	84	_	_
4-24	675-688	schizophrenia	_	_
4-25	689-697	patients	_	_
4-26	697-698	,	_	_
4-27	699-702	106	_	_
4-28	703-705	of	_	_
4-29	706-711	their	_	_
4-30	712-722	unaffected	_	_
4-31	723-731	siblings	_	_
4-32	732-735	and	_	_
4-33	736-738	63	_	_
4-34	739-746	healthy	_	_
4-35	747-755	controls	_	_
4-36	755-756	.	_	_

5-1	757-773	Interhemispheric	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
5-2	774-786	connectivity	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
5-3	787-790	and	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
5-4	791-802	hemispheric	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
5-5	803-817	specialization	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
5-6	818-822	were	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	http://maven.renci.org/NeuroBridge/neurobridge#Thing
5-7	823-833	calculated	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	http://maven.renci.org/NeuroBridge/neurobridge#Thing
5-8	834-838	from	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	http://maven.renci.org/NeuroBridge/neurobridge#Thing
5-9	839-852	resting-state	_	_
5-10	853-863	functional	_	_
5-11	864-876	connectivity	_	_
5-12	876-877	,	_	_
5-13	878-881	and	_	_
5-14	882-890	compared	_	_
5-15	891-897	across	_	_
5-16	898-904	groups	_	_
5-17	904-905	.	_	_

6-1	906-913	Results	_	_
6-2	914-920	showed	_	_
6-3	921-925	that	_	_
6-4	926-939	schizophrenia	_	_
6-5	940-948	patients	_	_
6-6	949-956	exhibit	_	_
6-7	957-962	lower	_	_
6-8	963-979	interhemispheric	_	_
6-9	980-992	connectivity	_	_
6-10	993-995	as	_	_
6-11	996-1004	compared	_	_
6-12	1005-1007	to	_	_
6-13	1008-1016	controls	_	_
6-14	1017-1020	and	_	_
6-15	1021-1029	siblings	_	_
6-16	1029-1030	.	_	_

7-1	1031-1033	In	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	_
7-2	1034-1042	addition	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
7-3	1042-1043	,	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
7-4	1044-1052	patients	_	_
7-5	1053-1059	showed	_	_
7-6	1060-1066	higher	_	_
7-7	1067-1073	levels	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
7-8	1074-1076	of	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
7-9	1077-1088	hemispheric	_	_
7-10	1089-1103	specialization	_	_
7-11	1104-1106	as	_	_
7-12	1107-1115	compared	_	_
7-13	1116-1118	to	_	_
7-14	1119-1127	siblings	_	_
7-15	1127-1128	.	_	_

8-1	1129-1134	Level	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
8-2	1135-1137	of	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
8-3	1138-1154	interhemispheric	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
8-4	1155-1167	connectivity	_	_
8-5	1168-1171	and	_	_
8-6	1172-1183	hemispheric	_	_
8-7	1184-1198	specialization	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
8-8	1199-1209	correlated	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
8-9	1210-1214	with	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
8-10	1215-1223	duration	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
8-11	1224-1226	of	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
8-12	1227-1234	illness	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
8-13	1235-1237	in	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
8-14	1238-1246	patients	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
8-15	1246-1247	.	_	_

9-1	1248-1250	No	_	_
9-2	1251-1262	significant	_	_
9-3	1263-1274	alterations	_	_
9-4	1275-1279	were	_	_
9-5	1280-1290	identified	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
9-6	1291-1293	in	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	_
9-7	1294-1302	siblings	_	_
9-8	1303-1311	relative	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_
9-9	1312-1314	to	_	_
9-10	1315-1323	controls	_	_
9-11	1324-1326	on	_	_
9-12	1327-1331	both	_	_
9-13	1332-1344	measurements	_	_
9-14	1344-1345	.	_	_

10-1	1346-1357	Furthermore	_	_
10-2	1357-1358	,	_	_
10-3	1359-1370	alterations	_	_
10-4	1371-1373	in	_	_
10-5	1374-1390	interhemispheric	_	_
10-6	1391-1403	connectivity	_	_
10-7	1404-1414	correlated	_	_
10-8	1415-1419	with	_	_
10-9	1420-1427	changes	_	_
10-10	1428-1430	in	_	_
10-11	1431-1442	hemispheric	_	_
10-12	1443-1457	specialization	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
10-13	1458-1460	in	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	_
10-14	1461-1469	patients	_	_
10-15	1470-1478	relative	_	_
10-16	1479-1481	to	_	_
10-17	1482-1490	controls	_	_
10-18	1491-1494	and	_	_
10-19	1495-1503	siblings	_	_
10-20	1503-1504	.	_	_

11-1	1505-1510	Taken	_	_
11-2	1511-1519	together	_	_
11-3	1519-1520	,	_	_
11-4	1521-1526	these	_	_
11-5	1527-1534	results	_	_
11-6	1535-1542	suggest	_	_
11-7	1543-1547	that	_	_
11-8	1548-1553	lower	_	_
11-9	1554-1570	interhemispheric	_	_
11-10	1571-1583	connectivity	_	_
11-11	1584-1587	and	_	_
11-12	1588-1598	associated	_	_
11-13	1599-1612	abnormalities	_	_
11-14	1613-1615	in	_	_
11-15	1616-1627	hemispheric	_	_
11-16	1628-1642	specialization	_	_
11-17	1643-1646	are	_	_
11-18	1647-1655	features	_	_
11-19	1656-1658	of	_	_
11-20	1659-1670	established	_	_
11-21	1671-1678	illness	_	_
11-22	1678-1679	,	_	_
11-23	1680-1686	rather	_	_
11-24	1687-1691	than	_	_
11-25	1692-1694	an	_	_
11-26	1695-1705	expression	_	_
11-27	1706-1708	of	_	_
11-28	1709-1720	preexistent	_	_
11-29	1721-1729	familial	_	_
11-30	1730-1734	risk	_	_
11-31	1735-1738	for	_	_
11-32	1739-1752	schizophrenia	_	_
11-33	1752-1753	.	_	_

12-1	1754-1764	Highlights	_	_
12-2	1765-1778	Schizophrenia	_	_
12-3	1779-1787	patients	_	_
12-4	1788-1792	show	_	_
12-5	1793-1798	lower	_	_
12-6	1799-1815	interhemispheric	_	_
12-7	1816-1828	connectivity	_	_
12-8	1829-1830	(	_	_
12-9	1830-1832	IC	_	_
12-10	1832-1833	)	_	_
12-11	1834-1842	compared	_	_
12-12	1843-1845	to	_	_
12-13	1846-1854	siblings	_	_
12-14	1855-1858	and	_	_
12-15	1859-1867	controls	_	_
12-16	1867-1868	.	_	_

13-1	1869-1874	Lower	_	_
13-2	1875-1877	IC	_	_
13-3	1878-1880	is	_	_
13-4	1881-1891	associated	_	_
13-5	1892-1896	with	_	_
13-6	1897-1903	higher	_	_
13-7	1904-1915	hemispheric	_	_
13-8	1916-1930	specialization	_	_
13-9	1931-1932	(	_	_
13-10	1932-1934	HS	_	_
13-11	1934-1935	)	_	_
13-12	1936-1938	in	_	_
13-13	1939-1947	patients	_	_
13-14	1947-1948	.	_	_

14-1	1949-1957	Siblings	_	_
14-2	1958-1960	do	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	_
14-3	1961-1964	not	_	_
14-4	1965-1969	show	_	_
14-5	1970-1977	changes	_	_
14-6	1978-1980	on	_	_
14-7	1981-1983	IC	_	_
14-8	1984-1987	and	_	_
14-9	1988-1990	HS	_	_
14-10	1991-1999	relative	_	_
14-11	2000-2002	to	_	_
14-12	2003-2011	controls	_	_
14-13	2011-2012	.	_	_

15-1	2013-2025	Connectivity	_	_
15-2	2026-2033	metrics	_	_
15-3	2034-2035	(	_	_
15-4	2035-2037	IC	_	_
15-5	2037-2038	,	_	_
15-6	2039-2041	HS	_	_
15-7	2041-2042	)	_	_
15-8	2043-2052	correlate	_	_
15-9	2053-2057	with	_	_
15-10	2058-2066	duration	_	_
15-11	2067-2069	of	_	_
15-12	2070-2077	illness	_	_
15-13	2078-2080	in	_	_
15-14	2081-2089	patients	_	_
15-15	2089-2090	.	_	_



















34-1	6154-6162	Material	_	_
34-2	6163-6166	and	_	_
34-3	6167-6174	methods	_	_
34-4	6175-6187	Participants	_	_
34-5	6188-6189	A	_	_
34-6	6190-6195	total	_	_
34-7	6196-6198	of	_	_
34-8	6199-6202	253	_	_
34-9	6203-6215	participants	_	_
34-10	6215-6216	,	_	_
34-11	6217-6226	including	_	_
34-12	6227-6229	84	_	_
34-13	6230-6243	schizophrenia	_	_
34-14	6244-6252	patients	_	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
34-15	6252-6253	,	_	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
34-16	6254-6257	106	_	_
34-17	6258-6260	of	_	_
34-18	6261-6266	their	_	_
34-19	6267-6277	unaffected	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	_
34-20	6278-6286	siblings	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	_
34-21	6287-6290	and	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
34-22	6291-6293	63	_	_
34-23	6294-6301	healthy	_	_
34-24	6302-6310	controls	_	_
34-25	6310-6311	,	_	_
34-26	6312-6316	were	_	_
34-27	6317-6326	recruited	_	_
34-28	6327-6329	at	_	_
34-29	6330-6333	the	_	_
34-30	6334-6344	University	_	_
34-31	6345-6352	Medical	_	_
34-32	6353-6359	Center	_	_
34-33	6360-6367	Utrecht	_	_
34-34	6368-6375	between	_	_
34-35	6376-6385	September	_	_
34-36	6386-6390	2004	_	_
34-37	6391-6394	and	_	_
34-38	6395-6400	April	_	_
34-39	6401-6405	2008	_	_
34-40	6405-6406	,	_	_
34-41	6407-6409	as	_	_
34-42	6410-6414	part	_	_
34-43	6415-6417	of	_	_
34-44	6418-6421	the	_	_
34-45	6422-6429	Genetic	_	_
34-46	6430-6434	Risk	_	_
34-47	6435-6438	and	_	_
34-48	6439-6446	Outcome	_	_
34-49	6447-6449	of	_	_
34-50	6450-6459	Psychosis	_	_
34-51	6460-6461	(	_	_
34-52	6461-6466	GROUP	_	_
34-53	6466-6467	)	_	_
34-54	6468-6473	study	_	_
34-55	6473-6474	.	_	_

35-1	6475-6478	The	_	_
35-2	6479-6484	GROUP	_	_
35-3	6485-6490	study	_	_
35-4	6491-6494	was	_	_
35-5	6495-6504	conducted	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
35-6	6505-6507	by	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
35-7	6508-6512	four	_	_
35-8	6513-6523	university	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
35-9	6524-6535	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
35-10	6536-6543	centers	_	_
35-11	6544-6547	and	_	_
35-12	6548-6553	their	_	_
35-13	6554-6564	affiliated	_	_
35-14	6565-6571	mental	_	_
35-15	6572-6578	health	_	_
35-16	6579-6583	care	_	_
35-17	6584-6596	institutions	_	_
35-18	6597-6599	in	_	_
35-19	6600-6603	the	_	_
35-20	6604-6615	Netherlands	_	_
35-21	6615-6616	.	_	_

36-1	6617-6620	The	_	_
36-2	6621-6628	medical	_	_
36-3	6629-6635	ethics	_	_
36-4	6636-6645	committee	_	_
36-5	6646-6648	of	_	_
36-6	6649-6652	the	_	_
36-7	6653-6663	University	_	_
36-8	6664-6671	Medical	_	_
36-9	6672-6678	Center	_	_
36-10	6679-6686	Utrecht	_	_
36-11	6687-6695	approved	_	_
36-12	6696-6699	the	_	_
36-13	6700-6707	current	_	_
36-14	6708-6713	study	_	_
36-15	6713-6714	.	_	_

37-1	6715-6718	All	_	_
37-2	6719-6727	subjects	_	_
37-3	6728-6736	provided	_	_
37-4	6737-6744	written	_	_
37-5	6745-6753	informed	_	_
37-6	6754-6761	consent	_	_
37-7	6762-6767	prior	_	_
37-8	6768-6770	to	_	_
37-9	6771-6784	participation	_	_
37-10	6784-6785	.	_	_

38-1	6786-6789	For	_	_
38-2	6790-6793	all	_	_
38-3	6794-6806	participants	_	_
38-4	6806-6807	,	_	_
38-5	6808-6816	presence	_	_
38-6	6817-6819	or	_	_
38-7	6820-6827	absence	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
38-8	6828-6830	of	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
38-9	6831-6838	current	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
38-10	6839-6842	and	_	_
38-11	6843-6851	lifetime	_	_
38-12	6852-6867	psychopathology	_	_
38-13	6868-6871	was	_	_
38-14	6872-6883	established	_	_
38-15	6884-6889	using	_	_
38-16	6890-6893	the	_	_
38-17	6894-6907	Comprehensive	_	_
38-18	6908-6918	Assessment	_	_
38-19	6919-6921	of	_	_
38-20	6922-6930	Symptoms	_	_
38-21	6931-6934	and	_	_
38-22	6935-6942	History	_	_
38-23	6943-6944	(	_	_
38-24	6944-6948	CASH	_	_
38-25	6948-6949	)	_	_
38-26	6949-6950	.	_	_

39-1	6951-6955	This	_	_
39-2	6956-6971	semi-structured	_	_
39-3	6972-6981	interview	_	_
39-4	6982-6984	is	_	_
39-5	6985-6993	designed	_	_
39-6	6994-6996	to	_	_
39-7	6997-7003	obtain	_	_
39-8	7004-7017	comprehensive	_	_
39-9	7018-7029	information	_	_
39-10	7030-7032	on	_	_
39-11	7033-7040	current	_	_
39-12	7041-7044	and	_	_
39-13	7045-7049	past	_	_
39-14	7050-7055	signs	_	_
39-15	7056-7059	and	_	_
39-16	7060-7068	symptoms	_	_
39-17	7069-7071	of	_	_
39-18	7072-7077	major	_	_
39-19	7078-7089	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
39-20	7090-7099	disorders	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
39-21	7099-7100	,	_	_
39-22	7101-7110	premorbid	_	_
39-23	7111-7122	functioning	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
39-24	7122-7123	,	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
39-25	7124-7140	sociodemographic	_	_
39-26	7141-7147	status	_	_
39-27	7147-7148	,	_	_
39-28	7149-7158	treatment	_	_
39-29	7158-7159	,	_	_
39-30	7160-7163	and	_	_
39-31	7164-7170	course	_	_
39-32	7171-7173	of	_	_
39-33	7174-7181	illness	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
39-34	7181-7182	.	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	_

40-1	7183-7191	Patients	_	_
40-2	7192-7196	were	_	_
40-3	7197-7205	included	_	_
40-4	7206-7208	if	_	_
40-5	7209-7213	they	_	_
40-6	7214-7217	met	_	_
40-7	7218-7228	Diagnostic	_	_
40-8	7229-7232	and	_	_
40-9	7233-7244	Statistical	_	_
40-10	7245-7251	Manual	_	_
40-11	7252-7254	of	_	_
40-12	7255-7261	Mental	_	_
40-13	7262-7271	Disorders	_	_
40-14	7272-7278	fourth	_	_
40-15	7279-7286	edition	_	_
40-16	7287-7288	(	_	_
40-17	7288-7294	DSM-IV	_	_
40-18	7294-7295	)	_	_
40-19	7296-7304	criteria	_	_
40-20	7305-7308	for	_	_
40-21	7309-7322	schizophrenia	_	_
40-22	7323-7325	or	_	_
40-23	7326-7341	schizoaffective	_	_
40-24	7342-7350	disorder	_	_
40-25	7350-7351	.	_	_

41-1	7352-7359	Symptom	_	_
41-2	7360-7368	severity	_	_
41-3	7369-7372	was	_	_
41-4	7373-7381	assessed	_	_
41-5	7382-7387	using	_	_
41-6	7388-7391	the	_	_
41-7	7392-7400	Positive	_	_
41-8	7401-7404	and	_	_
41-9	7405-7413	Negative	_	_
41-10	7414-7422	Syndrome	_	_
41-11	7423-7428	Scale	_	_
41-12	7429-7430	(	_	_
41-13	7430-7435	PANSS	_	_
41-14	7435-7436	)	_	_
41-15	7436-7437	.	_	_

42-1	7438-7441	The	_	_
42-2	7442-7448	dosage	_	_
42-3	7449-7451	of	_	_
42-4	7452-7465	antipsychotic	_	_
42-5	7466-7476	medication	_	_
42-6	7477-7485	patients	_	_
42-7	7486-7490	were	_	_
42-8	7491-7497	taking	_	_
42-9	7498-7500	at	_	_
42-10	7501-7504	the	_	_
42-11	7505-7509	time	_	_
42-12	7510-7512	of	_	_
42-13	7513-7521	scanning	_	_
42-14	7522-7526	were	_	_
42-15	7527-7536	converted	_	_
42-16	7537-7539	to	_	_
42-17	7540-7541	a	_	_
42-18	7542-7556	chlorpromazine	_	_
42-19	7557-7567	equivalent	_	_
42-20	7568-7574	dosage	_	_
42-21	7574-7575	.	_	_

43-1	7576-7587	Demographic	_	_
43-2	7588-7591	and	_	_
43-3	7592-7600	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
43-4	7601-7612	information	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
43-5	7613-7615	of	_	_
43-6	7616-7619	the	_	_
43-7	7620-7625	three	_	_
43-8	7626-7632	groups	_	_
43-9	7633-7635	of	_	_
43-10	7636-7648	participants	_	_
43-11	7649-7650	(	_	_
43-12	7650-7658	controls	_	_
43-13	7658-7659	,	_	_
43-14	7660-7668	siblings	_	_
43-15	7668-7669	,	_	_
43-16	7670-7683	schizophrenia	_	_
43-17	7684-7685	N	_	_
43-18	7685-7686	 	_	_
43-19	7686-7687	=	_	_
43-20	7687-7688	 	_	_
43-21	7688-7690	63	_	_
43-22	7690-7691	,	_	_
43-23	7692-7695	106	_	_
43-24	7695-7696	,	_	_
43-25	7697-7699	84	_	_
43-26	7699-7700	)	_	_
43-27	7700-7701	.	_	_

44-1	7702-7707	Table	_	_
44-2	7708-7709	1	_	_
44-3	7714-7722	Controls	_	_
44-4	7723-7731	Siblings	_	_
44-5	7732-7740	Patients	_	_
44-6	7741-7752	Statisticsa	_	_
44-7	7755-7758	Age	_	_
44-8	7759-7764	29.16	_	_
44-9	7764-7765	 	_	_
44-10	7765-7766	±	_	_
44-11	7766-7767	 	_	_
44-12	7767-7771	7.59	_	_
44-13	7772-7777	29.50	_	_
44-14	7777-7778	 	_	_
44-15	7778-7779	±	_	_
44-16	7779-7780	 	_	_
44-17	7780-7784	7.65	_	_
44-18	7785-7790	29.86	_	_
44-19	7790-7791	 	_	_
44-20	7791-7792	±	_	_
44-21	7792-7793	 	_	_
44-22	7793-7797	5.27	_	_
44-23	7798-7799	F	_	_
44-24	7799-7800	(	_	_
44-25	7800-7805	2,250	_	_
44-26	7805-7806	)	_	_
44-27	7806-7807	 	_	_
44-28	7807-7808	=	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_
44-29	7808-7809	 	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_
44-30	7809-7813	0.18	_	_
44-31	7813-7814	,	_	_
44-32	7815-7816	p	_	_
44-33	7816-7817	 	_	_
44-34	7817-7818	=	_	_
44-35	7818-7819	 	_	_
44-36	7819-7822	.83	_	_
44-37	7825-7828	Sex	_	_
44-38	7829-7830	(	_	_
44-39	7830-7831	M	_	_
44-40	7832-7833	/	_	_
44-41	7834-7835	F	_	_
44-42	7835-7836	)	_	_
44-43	7837-7839	29	_	_
44-44	7839-7840	/	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
44-45	7840-7842	34	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
44-46	7843-7845	49	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
44-47	7846-7847	/	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
44-48	7848-7850	57	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
44-49	7851-7853	70	_	_
44-50	7853-7854	/	_	_
44-51	7854-7856	14	_	_
44-52	7857-7858	χ	_	_
44-53	7858-7859	(	_	_
44-54	7859-7860	2	_	_
44-55	7860-7861	)	_	_
44-56	7861-7862	2	_	_
44-57	7862-7863	 	_	_
44-58	7863-7864	=	_	_
44-59	7864-7865	 	_	_
44-60	7865-7870	31.95	_	_
44-61	7870-7871	,	_	_
44-62	7872-7873	p	_	_
44-63	7873-7874	 	_	_
44-64	7874-7875	<	_	_
44-65	7875-7876	 	_	_
44-66	7876-7880	.001	_	_
44-67	7883-7885	IQ	_	_
44-68	7886-7892	113.76	_	_
44-69	7892-7893	 	_	_
44-70	7893-7894	±	_	_
44-71	7894-7895	 	_	_
44-72	7895-7900	15.66	_	_
44-73	7901-7907	105.96	_	_
44-74	7907-7908	 	_	_
44-75	7908-7909	±	_	_
44-76	7909-7910	 	_	_
44-77	7910-7915	17.10	_	_
44-78	7916-7921	95.99	_	_
44-79	7921-7922	 	_	_
44-80	7922-7923	±	_	_
44-81	7923-7924	 	_	_
44-82	7924-7929	15.21	_	_
44-83	7930-7931	F	_	_
44-84	7931-7932	(	_	_
44-85	7932-7937	2,250	_	_
44-86	7937-7938	)	_	_
44-87	7938-7939	 	_	_
44-88	7939-7940	=	_	_
44-89	7940-7941	 	_	_
44-90	7941-7946	20.54	_	_
44-91	7946-7947	,	_	_
44-92	7948-7949	p	_	_
44-93	7949-7950	 	_	_
44-94	7950-7951	<	_	_
44-95	7951-7952	 	_	_
44-96	7952-7956	.001	_	_
44-97	7959-7969	Handedness	_	_
44-98	7970-7971	(	_	_
44-99	7971-7976	right	_	_
44-100	7977-7978	/	_	_
44-101	7979-7983	left	_	_
44-102	7984-7985	/	_	_
44-103	7986-7991	mixed	_	_
44-104	7991-7992	)	_	_
44-105	7993-7995	44	_	_
44-106	7995-7996	/	_	_
44-107	7996-7997	8	_	_
44-108	7997-7998	/	_	_
44-109	7998-7999	1	_	_
44-110	8000-8002	94	_	_
44-111	8002-8003	/	_	_
44-112	8003-8004	6	_	_
44-113	8004-8005	/	_	_
44-114	8005-8006	6	_	_
44-115	8007-8009	70	_	_
44-116	8009-8010	/	_	_
44-117	8010-8011	5	_	_
44-118	8011-8012	/	_	_
44-119	8012-8013	4	_	_
44-120	8014-8015	χ	_	_
44-121	8015-8016	(	_	_
44-122	8016-8017	2	_	_
44-123	8017-8018	)	_	_
44-124	8018-8019	2	_	_
44-125	8019-8020	 	_	_
44-126	8020-8021	=	_	_
44-127	8021-8022	 	_	_
44-128	8022-8026	5.63	_	_
44-129	8026-8027	,	_	_
44-130	8028-8029	p	_	_
44-131	8029-8030	 	_	_
44-132	8030-8031	=	_	_
44-133	8031-8032	 	_	_
44-134	8032-8035	.23	_	_
44-135	8038-8045	Scanner	_	_
44-136	8046-8047	(	_	_
44-137	8047-8049	#1	_	_
44-138	8050-8051	/	_	_
44-139	8052-8054	#2	_	_
44-140	8054-8055	)	_	_
44-141	8056-8058	28	_	_
44-142	8059-8060	/	_	_
44-143	8061-8063	28	_	_
44-144	8064-8066	59	_	_
44-145	8067-8068	/	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
44-146	8069-8071	47	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
44-147	8072-8074	49	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
44-148	8075-8076	/	_	_
44-149	8077-8079	33	_	_
44-150	8080-8081	χ	_	_
44-151	8081-8082	(	_	_
44-152	8082-8083	2	_	_
44-153	8083-8084	)	_	_
44-154	8084-8085	2	_	_
44-155	8085-8086	 	_	_
44-156	8086-8087	=	_	_
44-157	8087-8088	 	_	_
44-158	8088-8092	1.28	_	_
44-159	8092-8093	,	_	_
44-160	8094-8095	p	_	_
44-161	8095-8096	 	_	_
44-162	8096-8097	=	_	_
44-163	8097-8098	 	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging	_
44-164	8098-8101	.53	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
44-165	8104-8111	Illness	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging	_
44-166	8112-8120	duration	_	_
44-167	8121-8122	(	_	_
44-168	8122-8127	years	_	_
44-169	8127-8128	)	_	_
44-170	8128-8129	b	_	http://maven.renci.org/NeuroBridge/neurobridge#WideRangeAchievementTest
44-171	8130-8131	–	_	http://maven.renci.org/NeuroBridge/neurobridge#WideRangeAchievementTest
44-172	8132-8133	–	_	_
44-173	8134-8138	5.91	_	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
44-174	8139-8140	(	_	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
44-175	8140-8144	4.12	_	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
44-176	8144-8145	)	_	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
44-177	8146-8147	–	_	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
44-178	8150-8164	Chlorpromazine	_	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
44-179	8165-8171	dosage	_	_
44-180	8172-8173	(	_	_
44-181	8173-8175	mg	_	_
44-182	8175-8176	/	_	_
44-183	8176-8179	day	_	_
44-184	8179-8180	)	_	_
44-185	8181-8182	–	_	_
44-186	8183-8184	–	_	_
44-187	8185-8188	300	_	_
44-188	8189-8190	(	_	_
44-189	8190-8193	200	_	_
44-190	8193-8194	,	_	_
44-191	8195-8198	600	_	_
44-192	8198-8199	)	_	_
44-193	8200-8201	–	_	_
44-194	8204-8209	PANSS	_	_
44-195	8210-8215	total	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
44-196	8216-8217	–	_	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
44-197	8218-8219	–	_	_
44-198	8220-8225	48.38	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
44-199	8225-8226	 	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
44-200	8226-8227	±	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
44-201	8227-8228	 	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
44-202	8228-8233	14.89	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
44-203	8234-8235	–	_	_
44-204	8238-8243	PANSS	_	_
44-205	8244-8252	positive	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
44-206	8253-8254	–	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	_
44-207	8255-8256	–	_	_
44-208	8257-8262	11.58	_	_
44-209	8262-8263	 	_	_
44-210	8263-8264	±	_	_
44-211	8264-8265	 	_	_
44-212	8265-8269	5.42	_	_
44-213	8270-8271	–	_	_
44-214	8274-8279	PANSS	_	_
44-215	8280-8288	negative	_	_
44-216	8289-8290	–	_	_
44-217	8291-8292	–	_	_
44-218	8293-8298	12.23	_	_
44-219	8298-8299	 	_	_
44-220	8299-8300	±	_	_
44-221	8300-8301	 	_	_
44-222	8301-8305	4.35	_	_
44-223	8306-8307	–	_	_
44-224	8310-8315	PANSS	_	_
44-225	8316-8323	general	_	_
44-226	8324-8339	psychopathology	_	_
44-227	8340-8341	–	_	_
44-228	8342-8343	–	_	_
44-229	8344-8349	24.57	_	_
44-230	8349-8350	 	_	_
44-231	8350-8351	±	_	_
44-232	8351-8352	 	_	_
44-233	8352-8356	7.05	_	_
44-234	8357-8358	–	_	_
44-235	8362-8367	Group	_	_
44-236	8368-8378	comparison	_	_
44-237	8379-8381	of	_	_
44-238	8382-8392	continuous	_	_
44-239	8393-8402	variables	_	_
44-240	8403-8404	(	_	_
44-241	8404-8407	Age	_	_
44-242	8407-8408	,	_	_
44-243	8409-8411	IQ	_	_
44-244	8411-8412	)	_	_
44-245	8413-8416	are	_	_
44-246	8417-8423	tested	_	_
44-247	8424-8428	with	_	_
44-248	8429-8436	one-way	_	_
44-249	8437-8445	analysis	_	_
44-250	8446-8448	of	_	_
44-251	8449-8457	variance	_	_
44-252	8458-8459	(	_	_
44-253	8459-8464	ANOVA	_	_
44-254	8464-8465	)	_	_
44-255	8465-8466	.	_	_

45-1	8467-8474	Nominal	_	_
45-2	8475-8484	variables	_	_
45-3	8485-8486	(	_	_
45-4	8486-8489	sex	_	_
45-5	8489-8490	,	_	_
45-6	8491-8501	handedness	_	_
45-7	8501-8502	,	_	_
45-8	8503-8510	scanner	_	_
45-9	8510-8511	)	_	_
45-10	8512-8516	were	_	_
45-11	8517-8525	compared	_	_
45-12	8526-8531	using	_	_
45-13	8532-8542	chi-square	_	_
45-14	8543-8553	statistics	_	_
45-15	8553-8554	.	_	_

46-1	8555-8567	Distribution	_	_
46-2	8568-8570	of	_	_
46-3	8571-8578	illness	_	_
46-4	8579-8587	duration	_	_
46-5	8588-8591	and	_	_
46-6	8592-8602	medication	_	_
46-7	8603-8605	is	_	_
46-8	8606-8612	skewed	_	_
46-9	8612-8613	,	_	_
46-10	8614-8623	therefore	_	_
46-11	8624-8630	median	_	_
46-12	8631-8634	and	_	_
46-13	8635-8649	inter-quartile	_	_
46-14	8650-8655	range	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
46-15	8656-8659	was	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
46-16	8660-8668	reported	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
46-17	8668-8669	.	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging

47-1	8670-8678	Patients	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
47-2	8679-8682	and	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
47-3	8683-8691	siblings	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
47-4	8692-8702	originated	_	_
47-5	8703-8707	from	_	_
47-6	8708-8711	120	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	_
47-7	8712-8718	unique	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
47-8	8719-8727	families	_	_
47-9	8728-8731	and	_	_
47-10	8732-8740	included	_	_
47-11	8741-8743	48	_	_
47-12	8744-8759	patient-sibling	_	_
47-13	8760-8765	pairs	_	_
47-14	8766-8768	or	_	_
47-15	8769-8777	triplets	_	_
47-16	8777-8778	.	_	_

48-1	8779-8782	The	_	_
48-2	8783-8790	control	_	_
48-3	8791-8796	group	_	_
48-4	8797-8806	comprised	_	_
48-5	8807-8809	63	_	_
48-6	8810-8818	subjects	_	_
48-7	8819-8823	from	_	_
48-8	8824-8826	57	_	_
48-9	8827-8835	families	_	_
48-10	8835-8836	.	_	_

49-1	8837-8838	A	_	_
49-2	8839-8845	family	_	_
49-3	8846-8860	identification	_	_
49-4	8861-8865	code	_	_
49-5	8866-8867	(	_	_
49-6	8867-8873	family	_	_
49-7	8874-8876	ID	_	_
49-8	8876-8877	)	_	_
49-9	8878-8881	was	_	_
49-10	8882-8890	assigned	_	_
49-11	8891-8893	to	_	_
49-12	8894-8899	every	_	_
49-13	8900-8907	subject	_	_
49-14	8908-8910	to	_	_
49-15	8911-8915	keep	_	_
49-16	8916-8921	track	_	_
49-17	8922-8924	of	_	_
49-18	8925-8930	their	_	_
49-19	8931-8940	pedigrees	_	_
49-20	8940-8941	.	_	_

50-1	8942-8950	Siblings	_	_
50-2	8951-8954	and	_	_
50-3	8955-8962	healthy	_	_
50-4	8963-8971	controls	_	_
50-5	8972-8976	were	_	_
50-6	8977-8985	excluded	_	_
50-7	8986-8989	for	_	_
50-8	8990-8993	any	_	_
50-9	8994-9001	current	_	_
50-10	9002-9004	or	_	_
50-11	9005-9013	previous	_	_
50-12	9014-9023	psychotic	_	_
50-13	9024-9032	disorder	_	_
50-14	9032-9033	.	_	_

51-1	9034-9036	In	_	_
51-2	9037-9045	addition	_	_
51-3	9045-9046	,	_	_
51-4	9047-9055	controls	_	_
51-5	9056-9060	were	_	_
51-6	9061-9069	examined	_	_
51-7	9070-9074	with	_	_
51-8	9075-9078	the	_	_
51-9	9079-9085	Family	_	_
51-10	9086-9095	Interview	_	_
51-11	9096-9099	for	_	_
51-12	9100-9107	Genetic	_	_
51-13	9108-9115	Studies	_	_
51-14	9115-9116	,	_	_
51-15	9117-9119	to	_	_
51-16	9120-9127	exclude	_	_
51-17	9128-9129	a	_	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
51-18	9130-9136	family	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
51-19	9137-9144	history	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
51-20	9145-9147	of	_	_
51-21	9148-9157	psychotic	_	_
51-22	9158-9167	disorders	_	_
51-23	9168-9169	(	_	_
51-24	9169-9171	in	_	_
51-25	9172-9177	first	_	_
51-26	9177-9178	-	_	_
51-27	9179-9181	or	_	_
51-28	9182-9195	second-degree	_	_
51-29	9196-9205	relatives	_	_
51-30	9205-9206	)	_	_
51-31	9206-9207	.	_	_

52-1	9208-9217	Exclusion	_	_
52-2	9218-9226	criteria	_	_
52-3	9227-9230	for	_	_
52-4	9231-9234	all	_	_
52-5	9235-9247	participants	_	_
52-6	9248-9256	included	_	_
52-7	9257-9258	a	_	_
52-8	9259-9266	history	_	_
52-9	9267-9269	of	_	_
52-10	9270-9274	head	_	_
52-11	9275-9281	trauma	_	_
52-12	9282-9284	or	_	_
52-13	9285-9290	major	_	_
52-14	9291-9298	medical	_	_
52-15	9299-9301	or	_	_
52-16	9302-9314	neurological	_	_
52-17	9315-9322	illness	_	_
52-18	9322-9323	.	_	_

53-1	9324-9327	All	_	_
53-2	9328-9340	participants	_	_
53-3	9341-9345	were	_	_
53-4	9346-9353	between	_	_
53-5	9354-9356	18	_	_
53-6	9357-9360	and	_	_
53-7	9361-9363	60	_	_
53-8	9363-9364	 	_	_
53-9	9364-9369	years	_	_
53-10	9370-9372	of	_	_
53-11	9373-9376	age	_	_
53-12	9377-9379	at	_	_
53-13	9380-9383	the	_	_
53-14	9384-9388	time	_	_
53-15	9389-9391	of	_	_
53-16	9392-9401	inclusion	_	_
53-17	9401-9402	.	_	_

54-1	9403-9415	Demographics	_	_
54-2	9416-9419	and	_	_
54-3	9420-9428	clinical	_	_
54-4	9429-9440	information	_	_
54-5	9441-9444	are	_	_
54-6	9445-9454	described	_	_
54-7	9455-9457	in	_	_
54-8	9458-9463	Table	_	_
54-9	9464-9465	1	_	_
54-10	9465-9466	.	_	_

55-1	9467-9471	Data	_	_
55-2	9472-9483	acquisition	_	_
55-3	9484-9487	MRI	_	_
55-4	9488-9493	scans	_	_
55-5	9494-9498	were	_	_
55-6	9499-9507	acquired	_	_
55-7	9508-9510	on	_	_
55-8	9511-9514	two	_	_
55-9	9515-9518	1.5	_	_
55-10	9518-9519	 	_	_
55-11	9519-9520	T	_	http://maven.renci.org/NeuroBridge/neurobridge#Cholesterol
55-12	9521-9528	Philips	_	http://maven.renci.org/NeuroBridge/neurobridge#Cholesterol
55-13	9529-9536	Achieva	_	http://maven.renci.org/NeuroBridge/neurobridge#Cholesterol
55-14	9537-9545	scanners	_	http://maven.renci.org/NeuroBridge/neurobridge#Cholesterol
55-15	9546-9548	at	_	_
55-16	9549-9552	the	_	_
55-17	9553-9563	University	_	_
55-18	9564-9571	Medical	_	_
55-19	9572-9578	Center	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
55-20	9579-9586	Utrecht	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
55-21	9586-9587	,	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
55-22	9588-9592	with	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
55-23	9593-9596	the	_	_
55-24	9597-9601	same	_	_
55-25	9602-9613	acquisition	_	_
55-26	9614-9622	protocol	_	_
55-27	9622-9623	.	_	_

56-1	9624-9627	The	_	_
56-2	9628-9635	scanner	_	_
56-3	9636-9647	information	_	_
56-4	9648-9651	was	_	_
56-5	9652-9660	included	_	_
56-6	9661-9663	as	_	_
56-7	9664-9665	a	_	_
56-8	9666-9675	covariate	_	_
56-9	9676-9678	in	_	_
56-10	9679-9686	further	_	_
56-11	9687-9704	group-comparisons	_	_
56-12	9704-9705	.	_	_

57-1	9706-9709	For	_	_
57-2	9710-9714	each	_	_
57-3	9715-9722	subject	_	_
57-4	9722-9723	,	_	_
57-5	9724-9737	resting-state	_	_
57-6	9738-9748	functional	_	_
57-7	9749-9757	magnetic	_	_
57-8	9758-9767	resonance	_	_
57-9	9768-9775	imaging	_	_
57-10	9776-9777	(	_	_
57-11	9777-9781	fMRI	_	_
57-12	9781-9782	)	_	_
57-13	9783-9787	time	_	_
57-14	9788-9794	series	_	_
57-15	9795-9799	were	_	_
57-16	9800-9808	acquired	_	_
57-17	9809-9813	with	_	_
57-18	9814-9815	a	_	_
57-19	9816-9821	three	_	_
57-20	9822-9833	dimensional	_	_
57-21	9834-9835	(	_	_
57-22	9835-9837	3D	_	_
57-23	9837-9838	)	_	_
57-24	9839-9843	echo	_	_
57-25	9844-9852	shifting	_	_
57-26	9853-9857	with	_	_
57-27	9858-9859	a	_	_
57-28	9860-9865	train	_	_
57-29	9866-9868	of	_	_
57-30	9869-9881	observations	_	_
57-31	9882-9883	(	_	_
57-32	9883-9889	PRESTO	_	_
57-33	9889-9890	)	_	_
57-34	9891-9902	acquisition	_	_
57-35	9903-9909	scheme	_	_
57-36	9909-9910	.	_	_

58-1	9911-9914	The	_	_
58-2	9915-9921	PRESTO	_	_
58-3	9922-9930	protocol	_	_
58-4	9931-9939	combines	_	_
58-5	9940-9943	the	_	_
58-6	9944-9948	echo	_	_
58-7	9949-9957	shifting	_	_
58-8	9958-9967	technique	_	_
58-9	9968-9972	with	_	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
58-10	9973-9981	multiple	_	_
58-11	9982-9990	gradient	_	_
58-12	9991-9997	echoes	_	_
58-13	9998-10001	per	_	_
58-14	10002-10012	excitation	_	_
58-15	10013-10015	to	_	_
58-16	10016-10021	allow	_	_
58-17	10022-10025	for	_	_
58-18	10026-10027	a	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
58-19	10028-10038	repetition	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol	_
58-20	10039-10043	time	_	_
58-21	10044-10051	shorter	_	_
58-22	10052-10056	than	_	_
58-23	10057-10061	echo	_	_
58-24	10062-10066	time	_	_
58-25	10066-10067	.	_	_

59-1	10068-10071	The	_	_
59-2	10072-10083	acquisition	_	_
59-3	10084-10094	parameters	_	_
59-4	10095-10099	were	_	_
59-5	10099-10100	:	_	_
59-6	10101-10103	TR	_	_
59-7	10104-10105	/	_	_
59-8	10106-10108	TE	_	_
59-9	10108-10109	 	_	_
59-10	10109-10110	=	_	_
59-11	10110-10111	 	_	_
59-12	10111-10115	21.1	_	_
59-13	10116-10117	/	_	_
59-14	10118-10122	31.1	_	_
59-15	10122-10123	 	_	_
59-16	10123-10125	ms	_	_
59-17	10125-10126	;	_	_
59-18	10127-10131	flip	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_
59-19	10132-10137	angle	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_
59-20	10137-10138	 	_	_
59-21	10138-10139	=	_	_
59-22	10139-10140	 	_	_
59-23	10140-10142	90	_	_
59-24	10142-10143	°	_	_
59-25	10143-10144	;	_	_
59-26	10145-10150	field	_	_
59-27	10151-10153	of	_	_
59-28	10154-10158	view	_	_
59-29	10158-10159	 	_	_
59-30	10159-10160	=	_	_
59-31	10160-10161	 	_	_
59-32	10161-10164	256	_	_
59-33	10164-10165	 	_	_
59-34	10165-10166	×	_	_
59-35	10166-10167	 	_	_
59-36	10167-10170	256	_	_
59-37	10170-10171	 	_	_
59-38	10171-10174	mm2	_	_
59-39	10174-10175	,	_	_
59-40	10176-10181	voxel	_	_
59-41	10182-10186	size	_	_
59-42	10186-10187	 	_	_
59-43	10187-10188	=	_	_
59-44	10188-10189	 	_	_
59-45	10189-10190	4	_	_
59-46	10190-10191	 	_	_
59-47	10191-10192	×	_	_
59-48	10192-10193	 	_	_
59-49	10193-10194	4	_	_
59-50	10194-10195	 	_	_
59-51	10195-10196	×	_	_
59-52	10196-10197	 	_	_
59-53	10197-10198	4	_	_
59-54	10198-10199	 	_	_
59-55	10199-10202	mm3	_	_
59-56	10202-10203	,	_	_
59-57	10204-10207	900	_	_
59-58	10208-10212	time	_	_
59-59	10213-10219	frames	_	_
59-60	10219-10220	,	_	_
59-61	10221-10231	consisting	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
59-62	10232-10234	of	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
59-63	10235-10237	32	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
59-64	10238-10244	slices	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
59-65	10245-10253	covering	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
59-66	10254-10259	whole	_	_
59-67	10260-10265	brain	_	_
59-68	10265-10266	.	_	_

60-1	10267-10269	In	_	_
60-2	10270-10278	addition	_	_
60-3	10278-10279	,	_	_
60-4	10280-10281	a	_	_
60-5	10282-10284	T1	_	_
60-6	10284-10285	-	_	_
60-7	10285-10293	weighted	_	_
60-8	10294-10298	scan	_	_
60-9	10299-10302	was	_	_
60-10	10303-10312	collected	_	_
60-11	10313-10315	as	_	_
60-12	10316-10326	anatomical	_	_
60-13	10327-10336	reference	_	_
60-14	10337-10341	with	_	_
60-15	10342-10345	the	_	_
60-16	10346-10355	following	_	_
60-17	10356-10364	scanning	_	_
60-18	10365-10375	parameters	_	_
60-19	10375-10376	:	_	_
60-20	10377-10379	TR	_	_
60-21	10379-10380	/	_	_
60-22	10380-10382	TE	_	_
60-23	10382-10383	 	_	_
60-24	10383-10384	=	_	_
60-25	10384-10385	 	_	_
60-26	10385-10387	30	_	_
60-27	10387-10388	/	_	_
60-28	10388-10391	4.6	_	_
60-29	10391-10392	 	_	_
60-30	10392-10394	ms	_	_
60-31	10394-10395	;	_	_
60-32	10396-10400	flip	_	_
60-33	10401-10406	angle	_	_
60-34	10406-10407	 	_	_
60-35	10407-10408	=	_	_
60-36	10408-10409	 	_	_
60-37	10409-10411	30	_	_
60-38	10411-10412	°	_	_
60-39	10412-10413	;	_	_
60-40	10414-10419	field	_	_
60-41	10420-10422	of	_	_
60-42	10423-10427	view	_	_
60-43	10427-10428	 	_	_
60-44	10428-10429	=	_	_
60-45	10429-10430	 	_	_
60-46	10430-10433	256	_	_
60-47	10433-10434	 	_	_
60-48	10434-10435	×	_	_
60-49	10435-10436	 	_	_
60-50	10436-10439	256	_	_
60-51	10439-10440	 	_	_
60-52	10440-10443	mm2	_	_
60-53	10443-10444	,	_	_
60-54	10445-10450	voxel	_	_
60-55	10451-10455	size	_	_
60-56	10455-10456	 	_	_
60-57	10456-10457	=	_	_
60-58	10457-10458	 	_	_
60-59	10458-10459	1	_	_
60-60	10459-10460	 	_	_
60-61	10460-10461	×	_	_
60-62	10461-10462	 	_	_
60-63	10462-10463	1	_	_
60-64	10463-10464	 	_	_
60-65	10464-10465	×	_	_
60-66	10465-10466	 	_	_
60-67	10466-10469	1.2	_	_
60-68	10469-10470	 	_	_
60-69	10470-10473	mm3	_	_
60-70	10473-10474	.	_	_

61-1	10475-10479	Data	_	_
61-2	10480-10493	preprocessing	_	_
61-3	10494-10507	Resting-state	_	_
61-4	10508-10512	fMRI	_	_
61-5	10513-10517	data	_	_
61-6	10518-10522	were	_	_
61-7	10523-10535	preprocessed	_	_
61-8	10536-10541	using	_	_
61-9	10542-10545	the	_	_
61-10	10546-10550	Data	_	_
61-11	10551-10561	Processing	_	_
61-12	10562-10565	and	_	_
61-13	10566-10574	Analysis	_	_
61-14	10575-10578	for	_	_
61-15	10579-10584	Brain	_	_
61-16	10585-10592	Imaging	_	_
61-17	10593-10594	(	_	_
61-18	10594-10599	DPABI	_	_
61-19	10599-10600	)	_	_
61-20	10601-10608	toolbox	_	_
61-21	10609-10611	on	_	_
61-22	10612-10618	MATLAB	_	_
61-23	10619-10620	v	_	_
61-24	10620-10621	.	_	_

62-1	10622-10628	R2016a	_	_
62-2	10629-10630	(	_	_
62-3	10630-10639	Mathworks	_	_
62-4	10639-10640	)	_	_
62-5	10640-10641	.	_	_

63-1	10642-10645	For	_	_
63-2	10646-10651	every	_	_
63-3	10652-10659	subject	_	_
63-4	10659-10660	,	_	_
63-5	10661-10664	the	_	_
63-6	10665-10670	first	_	_
63-7	10671-10673	10	_	_
63-8	10674-10684	functional	_	_
63-9	10685-10692	volumes	_	_
63-10	10693-10697	were	_	_
63-11	10698-10705	removed	_	_
63-12	10706-10708	to	_	_
63-13	10709-10714	allow	_	_
63-14	10715-10718	for	_	_
63-15	10719-10725	signal	_	_
63-16	10726-10739	stabilization	_	_
63-17	10739-10740	.	_	_

64-1	10741-10744	The	_	_
64-2	10745-10749	rest	_	_
64-3	10750-10752	of	_	_
64-4	10753-10756	the	_	_
64-5	10757-10767	functional	_	_
64-6	10768-10774	images	_	_
64-7	10775-10779	were	_	_
64-8	10780-10789	realigned	_	_
64-9	10789-10790	,	_	_
64-10	10791-10804	co-registered	_	_
64-11	10805-10809	with	_	_
64-12	10810-10815	their	_	_
64-13	10816-10826	individual	_	_
64-14	10827-10835	anatomic	_	_
64-15	10836-10841	image	_	_
64-16	10841-10842	,	_	_
64-17	10843-10846	and	_	_
64-18	10847-10856	corrected	_	_
64-19	10857-10860	for	_	_
64-20	10861-10869	nuisance	_	_
64-21	10870-10879	variables	_	_
64-22	10880-10881	(	_	_
64-23	10881-10884	six	_	_
64-24	10885-10890	rigid	_	_
64-25	10891-10902	realignment	_	_
64-26	10903-10913	parameters	_	_
64-27	10913-10914	,	_	_
64-28	10915-10921	signal	_	_
64-29	10922-10927	drift	_	_
64-30	10927-10928	,	_	_
64-31	10929-10937	averaged	_	_
64-32	10938-10944	signal	_	_
64-33	10945-10949	from	_	_
64-34	10950-10955	white	_	_
64-35	10956-10962	matter	_	_
64-36	10963-10966	and	_	_
64-37	10967-10980	cerebrospinal	_	_
64-38	10981-10986	fluid	_	_
64-39	10986-10987	)	_	_
64-40	10988-10993	using	_	_
64-41	10994-10995	a	_	_
64-42	10996-11002	linear	_	_
64-43	11003-11013	regression	_	_
64-44	11014-11019	model	_	_
64-45	11019-11020	.	_	_

65-1	11021-11030	Band-pass	_	_
65-2	11031-11040	filtering	_	_
65-3	11041-11042	(	_	_
65-4	11042-11046	0.01	_	_
65-5	11046-11047	–	_	_
65-6	11047-11050	0.1	_	_
65-7	11050-11051	 	_	_
65-8	11051-11053	Hz	_	_
65-9	11053-11054	)	_	_
65-10	11055-11058	was	_	_
65-11	11059-11066	applied	_	_
65-12	11067-11069	to	_	_
65-13	11070-11074	fMRI	_	_
65-14	11075-11086	time-series	_	_
65-15	11087-11089	to	_	_
65-16	11090-11096	reduce	_	_
65-17	11097-11104	effects	_	_
65-18	11105-11107	of	_	_
65-19	11108-11121	low-frequency	_	_
65-20	11122-11128	drifts	_	_
65-21	11129-11132	and	_	_
65-22	11133-11147	high-frequency	_	_
65-23	11148-11153	noise	_	_
65-24	11153-11154	.	_	_

66-1	11155-11167	Subsequently	_	_
66-2	11167-11168	,	_	_
66-3	11169-11172	the	_	_
66-4	11173-11183	functional	_	_
66-5	11184-11189	scans	_	_
66-6	11190-11194	were	_	_
66-7	11195-11204	spatially	_	_
66-8	11205-11215	normalized	_	_
66-9	11216-11218	to	_	_
66-10	11219-11222	MNI	_	_
66-11	11223-11228	space	_	_
66-12	11229-11234	using	_	_
66-13	11235-11236	a	_	_
66-14	11237-11246	symmetric	_	_
66-15	11247-11261	group-specific	_	_
66-16	11262-11264	T1	_	_
66-17	11265-11273	template	_	_
66-18	11273-11274	,	_	_
66-19	11275-11278	and	_	_
66-20	11279-11288	resampled	_	_
66-21	11289-11291	to	_	_
66-22	11292-11293	3	_	_
66-23	11293-11294	 	_	_
66-24	11294-11295	×	_	_
66-25	11295-11296	 	_	_
66-26	11296-11297	3	_	_
66-27	11297-11298	 	_	_
66-28	11298-11299	×	_	_
66-29	11299-11300	 	_	_
66-30	11300-11301	3	_	_
66-31	11301-11302	 	_	_
66-32	11302-11305	mm3	_	_
66-33	11306-11312	voxels	_	_
66-34	11312-11313	.	_	_

67-1	11314-11321	Spatial	_	_
67-2	11322-11331	smoothing	_	_
67-3	11332-11335	was	_	_
67-4	11336-11343	applied	_	_
67-5	11344-11346	to	_	_
67-6	11347-11357	normalized	_	_
67-7	11358-11364	images	_	_
67-8	11365-11369	with	_	_
67-9	11370-11371	a	_	_
67-10	11372-11373	4	_	_
67-11	11373-11374	 	_	_
67-12	11374-11376	mm	_	_
67-13	11377-11387	full-width	_	_
67-14	11388-11400	half-maximum	_	_
67-15	11401-11402	(	_	_
67-16	11402-11406	FWHM	_	_
67-17	11406-11407	)	_	_
67-18	11408-11416	Gaussian	_	_
67-19	11417-11423	kernel	_	_
67-20	11423-11424	.	_	_

68-1	11425-11427	In	_	_
68-2	11428-11432	view	_	_
68-3	11433-11435	of	_	_
68-4	11436-11442	recent	_	_
68-5	11443-11451	findings	_	_
68-6	11452-11454	on	_	_
68-7	11455-11458	the	_	_
68-8	11459-11468	influence	_	_
68-9	11469-11471	of	_	_
68-10	11472-11482	in-scanner	_	_
68-11	11483-11487	head	_	_
68-12	11488-11494	motion	_	_
68-13	11495-11497	on	_	_
68-14	11498-11502	fMRI	_	_
68-15	11503-11510	signals	_	_
68-16	11510-11511	,	_	_
68-17	11512-11518	images	_	_
68-18	11519-11523	with	_	_
68-19	11524-11533	excessive	_	_
68-20	11534-11542	movement	_	_
68-21	11543-11544	(	_	_
68-22	11544-11554	frame-wise	_	_
68-23	11555-11567	displacement	_	_
68-24	11568-11569	>	_	_
68-25	11569-11572	0.5	_	_
68-26	11572-11573	 	_	_
68-27	11573-11575	mm	_	_
68-28	11575-11576	)	_	_
68-29	11577-11580	and	_	_
68-30	11581-11582	1	_	_
68-31	11583-11591	backward	_	_
68-32	11592-11595	and	_	_
68-33	11596-11597	2	_	_
68-34	11598-11605	forward	_	_
68-35	11606-11611	scans	_	_
68-36	11612-11620	relative	_	_
68-37	11621-11623	to	_	_
68-38	11624-11627	the	_	_
68-39	11628-11634	marked	_	_
68-40	11635-11640	frame	_	_
68-41	11640-11641	,	_	_
68-42	11642-11646	were	_	_
68-43	11647-11655	scrubbed	_	_
68-44	11655-11656	.	_	_

69-1	11657-11660	The	_	_
69-2	11661-11670	scrubbing	_	_
69-3	11671-11680	procedure	_	_
69-4	11681-11688	negated	_	_
69-5	11689-11706	group-differences	_	_
69-6	11707-11709	in	_	_
69-7	11710-11714	head	_	_
69-8	11715-11721	motion	_	_
69-9	11722-11723	(	_	_
69-10	11723-11729	before	_	_
69-11	11730-11739	scrubbing	_	_
69-12	11740-11741	χ	_	_
69-13	11741-11742	(	_	_
69-14	11742-11743	2	_	_
69-15	11743-11744	)	_	_
69-16	11744-11745	2	_	_
69-17	11745-11746	 	_	_
69-18	11746-11747	=	_	_
69-19	11747-11748	 	_	_
69-20	11748-11752	6.20	_	_
69-21	11752-11753	,	_	_
69-22	11754-11755	p	_	_
69-23	11755-11756	 	_	_
69-24	11756-11757	=	_	_
69-25	11757-11758	 	_	_
69-26	11758-11761	.04	_	_
69-27	11762-11765	and	_	_
69-28	11766-11771	after	_	_
69-29	11772-11781	scrubbing	_	_
69-30	11782-11783	χ	_	_
69-31	11783-11784	(	_	_
69-32	11784-11785	2	_	_
69-33	11785-11786	)	_	_
69-34	11786-11787	2	_	_
69-35	11787-11788	 	_	_
69-36	11788-11789	=	_	_
69-37	11789-11790	 	_	_
69-38	11790-11794	4.09	_	_
69-39	11794-11795	,	_	_
69-40	11796-11797	p	_	_
69-41	11797-11798	 	_	_
69-42	11798-11799	=	_	_
69-43	11799-11800	 	_	_
69-44	11800-11803	.13	_	_
69-45	11803-11804	,	_	_
69-46	11805-11818	Supplementary	_	_
69-47	11819-11824	Table	_	_
69-48	11825-11826	1	_	_
69-49	11826-11827	)	_	_
69-50	11827-11828	,	_	_
69-51	11829-11832	and	_	_
69-52	11833-11836	did	_	_
69-53	11837-11840	not	_	_
69-54	11841-11845	lead	_	_
69-55	11846-11848	to	_	_
69-56	11849-11860	differences	_	_
69-57	11861-11863	on	_	_
69-58	11864-11867	the	_	_
69-59	11868-11874	number	_	_
69-60	11875-11877	of	_	_
69-61	11878-11884	images	_	_
69-62	11885-11893	rejected	_	_
69-63	11894-11899	among	_	_
69-64	11900-11903	the	_	_
69-65	11904-11909	three	_	_
69-66	11910-11917	subject	_	_
69-67	11918-11924	groups	_	_
69-68	11925-11926	(	_	_
69-69	11926-11927	χ	_	_
69-70	11927-11928	(	_	_
69-71	11928-11929	2	_	_
69-72	11929-11930	)	_	_
69-73	11930-11931	2	_	_
69-74	11931-11932	 	_	_
69-75	11932-11933	=	_	_
69-76	11933-11934	 	_	_
69-77	11934-11938	3.54	_	_
69-78	11938-11939	,	_	_
69-79	11940-11941	p	_	_
69-80	11941-11942	 	_	_
69-81	11942-11943	=	_	_
69-82	11943-11944	 	_	_
69-83	11944-11947	.17	_	_
69-84	11947-11948	)	_	_
69-85	11948-11949	.	_	_

70-1	11950-11953	The	_	_
70-2	11954-11968	Harvard-Oxford	_	_
70-3	11969-11974	atlas	_	_
70-4	11975-11978	was	_	_
70-5	11979-11986	applied	_	_
70-6	11987-11989	to	_	_
70-7	11990-12001	whole-brain	_	_
70-8	12002-12012	functional	_	_
70-9	12013-12017	data	_	_
70-10	12018-12020	in	_	_
70-11	12021-12026	order	_	_
70-12	12027-12029	to	_	_
70-13	12030-12040	parcellate	_	_
70-14	12041-12044	the	_	_
70-15	12045-12050	brain	_	_
70-16	12051-12055	into	_	_
70-17	12056-12059	112	_	_
70-18	12060-12069	bilateral	_	_
70-19	12070-12077	regions	_	_
70-20	12078-12079	(	_	_
70-21	12079-12081	48	_	_
70-22	12082-12090	cortical	_	_
70-23	12091-12094	and	_	_
70-24	12095-12096	8	_	_
70-25	12097-12108	subcortical	_	_
70-26	12109-12116	regions	_	_
70-27	12117-12120	per	_	_
70-28	12121-12131	hemisphere	_	_
70-29	12131-12132	)	_	_
70-30	12132-12133	.	_	_

71-1	12134-12140	Region	_	_
71-2	12141-12146	names	_	_
71-3	12146-12147	,	_	_
71-4	12148-12161	abbreviations	_	_
71-5	12161-12162	,	_	_
71-6	12163-12171	anatomic	_	_
71-7	12172-12186	classification	_	_
71-8	12187-12188	(	_	_
71-9	12188-12195	frontal	_	_
71-10	12195-12196	,	_	_
71-11	12197-12205	temporal	_	_
71-12	12205-12206	,	_	_
71-13	12207-12215	parietal	_	_
71-14	12215-12216	,	_	_
71-15	12217-12226	occipital	_	_
71-16	12227-12231	lobe	_	_
71-17	12231-12232	,	_	_
71-18	12233-12242	cingulate	_	_
71-19	12243-12249	cortex	_	_
71-20	12250-12253	and	_	_
71-21	12254-12265	subcortical	_	_
71-22	12266-12273	regions	_	_
71-23	12273-12274	)	_	_
71-24	12275-12278	and	_	_
71-25	12279-12289	functional	_	_
71-26	12290-12299	hierarchy	_	_
71-27	12300-12301	(	_	_
71-28	12301-12308	primary	_	_
71-29	12309-12321	sensorimotor	_	_
71-30	12322-12329	regions	_	_
71-31	12329-12330	,	_	_
71-32	12331-12339	unimodal	_	_
71-33	12339-12340	,	_	_
71-34	12341-12352	heteromodal	_	_
71-35	12353-12364	association	_	_
71-36	12365-12370	areas	_	_
71-37	12370-12371	,	_	_
71-38	12372-12373	(	_	_
71-39	12373-12377	para	_	_
71-40	12377-12378	)	_	_
71-41	12378-12384	limbic	_	_
71-42	12385-12388	and	_	_
71-43	12389-12400	subcortical	_	_
71-44	12401-12408	regions	_	_
71-45	12408-12409	)	_	_
71-46	12410-12413	are	_	_
71-47	12414-12424	referenced	_	_
71-48	12425-12427	in	_	_
71-49	12428-12441	Supplementary	_	_
71-50	12442-12447	Table	_	_
71-51	12448-12449	2	_	_
71-52	12449-12450	.	_	_

72-1	12451-12454	The	_	_
72-2	12455-12465	functional	_	_
72-3	12466-12475	hierarchy	_	_
72-4	12476-12487	subdivision	_	_
72-5	12488-12494	scheme	_	_
72-6	12495-12497	is	_	_
72-7	12498-12503	based	_	_
72-8	12504-12506	on	_	_
72-9	12507-12515	previous	_	_
72-10	12516-12523	studies	_	_
72-11	12523-12524	.	_	_

73-1	12525-12533	Regional	_	_
73-2	12534-12545	time-series	_	_
73-3	12546-12550	were	_	_
73-4	12551-12559	averaged	_	_
73-5	12560-12566	across	_	_
73-6	12567-12573	voxels	_	_
73-7	12573-12574	,	_	_
73-8	12575-12578	and	_	_
73-9	12579-12595	cross-correlated	_	_
73-10	12596-12599	for	_	_
73-11	12600-12604	each	_	_
73-12	12605-12609	pair	_	_
73-13	12610-12612	of	_	_
73-14	12613-12618	brain	_	_
73-15	12619-12626	regions	_	_
73-16	12627-12632	using	_	_
73-17	12633-12642	Pearson's	_	_
73-18	12643-12654	correlation	_	_
73-19	12654-12655	.	_	_

74-1	12656-12667	Correlation	_	_
74-2	12668-12680	coefficients	_	_
74-3	12681-12685	were	_	_
74-4	12686-12695	converted	_	_
74-5	12696-12698	to	_	_
74-6	12699-12700	z	_	_
74-7	12701-12707	scores	_	_
74-8	12708-12713	using	_	_
74-9	12714-12722	Fisher's	_	_
74-10	12723-12724	z	_	_
74-11	12725-12739	transformation	_	_
74-12	12739-12740	,	_	_
74-13	12741-12748	serving	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
74-14	12749-12751	as	_	_
74-15	12752-12753	a	_	_
74-16	12754-12761	measure	_	_
74-17	12762-12764	of	_	_
74-18	12765-12775	functional	_	_
74-19	12776-12788	connectivity	_	_
74-20	12789-12797	strength	_	_
74-21	12798-12805	between	_	_
74-22	12806-12809	two	_	_
74-23	12810-12817	regions	_	_
74-24	12817-12818	.	_	_

75-1	12819-12835	Interhemispheric	_	_
75-2	12836-12848	connectivity	_	_
75-3	12849-12852	The	_	_
75-4	12853-12858	level	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
75-5	12859-12861	of	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
75-6	12862-12872	functional	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
75-7	12873-12885	connectivity	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
75-8	12886-12893	between	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
75-9	12894-12896	56	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
75-10	12897-12904	regions	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
75-11	12905-12907	in	_	_
75-12	12908-12911	one	_	_
75-13	12912-12922	hemisphere	_	_
75-14	12923-12926	and	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
75-15	12927-12932	their	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
75-16	12933-12946	corresponding	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
75-17	12947-12952	areas	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
75-18	12953-12955	in	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
75-19	12956-12959	the	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
75-20	12960-12965	other	_	_
75-21	12966-12976	hemisphere	_	_
75-22	12977-12979	is	_	_
75-23	12980-12984	used	_	_
75-24	12985-12989	here	_	_
75-25	12990-12992	as	_	_
75-26	12993-12996	the	_	_
75-27	12997-13004	measure	_	_
75-28	13005-13007	of	_	_
75-29	13008-13024	interhemispheric	_	_
75-30	13025-13037	connectivity	_	_
75-31	13037-13038	.	_	_

76-1	13039-13055	Interhemispheric	_	_
76-2	13056-13067	connections	_	_
76-3	13068-13075	between	_	_
76-4	13076-13085	homotopic	_	_
76-5	13086-13093	regions	_	_
76-6	13094-13097	are	_	_
76-7	13098-13103	among	_	_
76-8	13104-13107	the	_	_
76-9	13108-13117	strongest	_	_
76-10	13118-13128	functional	_	_
76-11	13129-13141	associations	_	_
76-12	13142-13144	in	_	_
76-13	13145-13162	cortical-cortical	_	_
76-14	13163-13175	interactions	_	_
76-15	13176-13179	and	_	_
76-16	13180-13184	have	_	_
76-17	13185-13193	reliably	_	_
76-18	13194-13198	been	_	_
76-19	13199-13209	identified	_	_
76-20	13210-13212	in	_	_
76-21	13213-13217	both	_	_
76-22	13218-13225	healthy	_	_
76-23	13226-13229	and	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
76-24	13230-13238	clinical	_	_
76-25	13239-13250	populations	_	_
76-26	13250-13251	.	_	_

77-1	13252-13254	As	_	_
77-2	13255-13256	a	_	_
77-3	13257-13270	supplementary	_	_
77-4	13271-13279	analysis	_	_
77-5	13279-13280	,	_	_
77-6	13281-13298	group-differences	_	_
77-7	13299-13301	in	_	_
77-8	13302-13313	heterotopic	_	_
77-9	13314-13330	interhemispheric	_	_
77-10	13331-13343	connectivity	_	_
77-11	13344-13347	and	_	_
77-12	13348-13352	left	_	_
77-13	13353-13356	and	_	_
77-14	13357-13362	right	_	_
77-15	13363-13379	intrahemispheric	_	_
77-16	13380-13392	connectivity	_	_
77-17	13393-13397	were	_	_
77-18	13398-13406	examined	_	_
77-19	13407-13409	in	_	_
77-20	13410-13413	the	_	_
77-21	13414-13418	same	_	_
77-22	13419-13425	manner	_	_
77-23	13426-13428	as	_	_
77-24	13429-13438	homotopic	_	_
77-25	13439-13455	interhemispheric	_	_
77-26	13456-13468	connectivity	_	_
77-27	13468-13469	.	_	_

78-1	13470-13478	Moreover	_	_
78-2	13478-13479	,	_	_
78-3	13480-13482	to	_	_
78-4	13483-13489	assess	_	_
78-5	13490-13493	the	_	_
78-6	13494-13505	consistency	_	_
78-7	13506-13508	of	_	_
78-8	13509-13525	interhemispheric	_	_
78-9	13526-13538	connectivity	_	_
78-10	13539-13551	measurements	_	_
78-11	13552-13559	between	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
78-12	13560-13567	studies	_	_
78-13	13567-13568	,	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
78-14	13569-13571	we	_	_
78-15	13572-13581	performed	_	_
78-16	13582-13584	an	_	_
78-17	13585-13595	additional	_	_
78-18	13596-13604	analysis	_	_
78-19	13605-13614	examining	_	_
78-20	13615-13618	the	_	_
78-21	13619-13630	correlation	_	_
78-22	13631-13633	in	_	_
78-23	13634-13642	regional	_	_
78-24	13643-13659	interhemispheric	_	_
78-25	13660-13672	connectivity	_	_
78-26	13673-13675	in	_	_
78-27	13676-13684	controls	_	_
78-28	13685-13692	between	_	_
78-29	13693-13697	this	_	_
78-30	13698-13703	study	_	_
78-31	13704-13707	and	_	_
78-32	13708-13711	the	_	_
78-33	13712-13717	study	_	_
78-34	13718-13720	of	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
78-35	13720-13721	.	_	_

79-1	13722-13733	Hemispheric	_	_
79-2	13734-13748	specialization	_	_
79-3	13749-13760	Hemispheric	_	_
79-4	13761-13775	specialization	_	_
79-5	13776-13778	is	_	_
79-6	13779-13789	calculated	_	_
79-7	13790-13794	here	_	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
79-8	13795-13797	as	_	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
79-9	13798-13801	the	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
79-10	13802-13812	difference	_	_
79-11	13813-13815	in	_	_
79-12	13816-13828	connectivity	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
79-13	13829-13837	strength	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
79-14	13838-13845	between	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
79-15	13846-13862	intrahemispheric	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
79-16	13863-13866	and	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
79-17	13867-13878	heterotopic	_	_
79-18	13879-13895	interhemispheric	_	_
79-19	13896-13907	connections	_	_
79-20	13908-13910	of	_	_
79-21	13911-13915	each	_	_
79-22	13916-13921	brain	_	_
79-23	13922-13928	region	_	_
79-24	13928-13929	.	_	_

80-1	13930-13939	Homotopic	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
80-2	13940-13956	interhemispheric	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
80-3	13957-13968	connections	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
80-4	13969-13973	were	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
80-5	13974-13977	not	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
80-6	13978-13982	used	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	_
80-7	13983-13985	in	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	_
80-8	13986-13989	the	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
80-9	13990-14001	calculation	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
80-10	14002-14004	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
80-11	14005-14016	hemispheric	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
80-12	14017-14031	specialization	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	_
80-13	14032-14034	so	_	_
80-14	14035-14039	that	_	_
80-15	14040-14042	we	_	_
80-16	14043-14048	could	_	_
80-17	14049-14056	examine	_	_
80-18	14057-14069	relationship	_	_
80-19	14070-14077	between	_	_
80-20	14078-14089	hemispheric	_	_
80-21	14090-14104	specialization	_	_
80-22	14105-14108	and	_	_
80-23	14109-14125	interhemispheric	_	_
80-24	14126-14138	connectivity	_	_
80-25	14139-14141	in	_	_
80-26	14142-14145	the	_	_
80-27	14146-14155	following	_	_
80-28	14156-14164	analysis	_	_
80-29	14164-14165	.	_	_

81-1	14166-14167	A	_	_
81-2	14168-14176	positive	_	_
81-3	14177-14182	value	_	_
81-4	14183-14185	of	_	_
81-5	14186-14197	hemispheric	_	_
81-6	14198-14212	specialization	_	_
81-7	14213-14222	indicates	_	_
81-8	14223-14227	that	_	_
81-9	14228-14229	a	_	_
81-10	14230-14236	region	_	_
81-11	14237-14239	or	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
81-12	14240-14250	hemisphere	_	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
81-13	14251-14253	is	_	_
81-14	14254-14268	preferentially	_	_
81-15	14269-14278	connected	_	_
81-16	14279-14281	to	_	_
81-17	14282-14287	other	_	_
81-18	14288-14295	regions	_	_
81-19	14296-14302	within	_	_
81-20	14303-14306	its	_	_
81-21	14307-14310	own	_	_
81-22	14311-14321	hemisphere	_	_
81-23	14321-14322	,	_	_
81-24	14323-14330	whereas	_	_
81-25	14331-14332	a	_	_
81-26	14333-14341	negative	_	_
81-27	14342-14347	value	_	_
81-28	14348-14356	suggests	_	_
81-29	14357-14361	that	_	_
81-30	14362-14363	a	_	_
81-31	14364-14370	region	_	_
81-32	14371-14373	or	_	_
81-33	14374-14384	hemisphere	_	_
81-34	14385-14387	is	_	_
81-35	14388-14392	more	_	_
81-36	14393-14401	strongly	_	_
81-37	14402-14411	connected	_	_
81-38	14412-14414	to	_	_
81-39	14415-14422	regions	_	_
81-40	14423-14425	in	_	_
81-41	14426-14429	the	_	_
81-42	14430-14443	contralateral	_	_
81-43	14444-14454	hemisphere	_	_
81-44	14454-14455	.	_	_

82-1	14456-14459	The	_	_
82-2	14460-14466	method	_	_
82-3	14467-14471	used	_	_
82-4	14472-14474	to	_	_
82-5	14475-14482	compute	_	_
82-6	14483-14494	hemispheric	_	_
82-7	14495-14509	specialization	_	_
82-8	14510-14515	using	_	_
82-9	14516-14525	intrinsic	_	_
82-10	14526-14536	functional	_	_
82-11	14537-14549	connectivity	_	_
82-12	14550-14553	has	_	_
82-13	14554-14558	been	_	_
82-14	14559-14568	described	_	_
82-15	14569-14571	in	_	_
82-16	14572-14580	previous	_	_
82-17	14581-14588	studies	_	_
82-18	14589-14594	using	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
82-19	14595-14596	a	_	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
82-20	14597-14608	voxel-based	_	_
82-21	14609-14617	analysis	_	_
82-22	14617-14618	.	_	_

83-1	14619-14630	Statistical	_	_
83-2	14631-14639	analysis	_	_
83-3	14640-14647	Effects	_	_
83-4	14648-14650	of	_	_
83-5	14651-14656	group	_	_
83-6	14657-14660	and	_	_
83-7	14661-14671	covariates	_	_
83-8	14672-14674	on	_	_
83-9	14675-14691	interhemispheric	_	_
83-10	14692-14704	connectivity	_	_
83-11	14705-14708	and	_	_
83-12	14709-14720	hemispheric	_	_
83-13	14721-14735	specialization	_	_
83-14	14736-14740	were	_	_
83-15	14741-14749	assessed	_	_
83-16	14750-14755	using	_	_
83-17	14756-14768	linear-mixed	_	_
83-18	14769-14775	effect	_	_
83-19	14776-14782	models	_	_
83-20	14782-14783	.	_	_

84-1	14784-14787	For	_	_
84-2	14788-14804	interhemispheric	_	_
84-3	14805-14817	connectivity	_	_
84-4	14817-14818	,	_	_
84-5	14819-14832	fixed-effects	_	_
84-6	14833-14840	include	_	_
84-7	14840-14841	:	_	_
84-8	14842-14847	group	_	_
84-9	14848-14854	status	_	_
84-10	14855-14856	(	_	_
84-11	14856-14864	controls	_	_
84-12	14864-14865	,	_	_
84-13	14866-14874	siblings	_	_
84-14	14874-14875	,	_	_
84-15	14876-14884	patients	_	_
84-16	14884-14885	)	_	_
84-17	14885-14886	,	_	_
84-18	14887-14890	age	_	_
84-19	14890-14891	,	_	_
84-20	14892-14895	sex	_	_
84-21	14895-14896	,	_	_
84-22	14897-14907	handedness	_	_
84-23	14908-14909	(	_	_
84-24	14909-14914	right	_	_
84-25	14915-14916	/	_	_
84-26	14917-14921	left	_	_
84-27	14922-14923	/	_	_
84-28	14924-14929	mixed	_	_
84-29	14929-14930	)	_	_
84-30	14930-14931	,	_	_
84-31	14932-14939	scanner	_	_
84-32	14940-14941	(	_	_
84-33	14941-14943	#1	_	_
84-34	14944-14945	/	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#Thing
84-35	14946-14948	#2	_	_
84-36	14948-14949	)	_	_
84-37	14950-14953	and	_	_
84-38	14954-14958	head	_	_
84-39	14959-14965	motion	_	_
84-40	14965-14966	.	_	_

85-1	14967-14969	To	_	_
85-2	14970-14977	control	_	_
85-3	14978-14981	for	_	_
85-4	14982-14991	potential	_	_
85-5	14992-15009	group-differences	_	_
85-6	15010-15012	in	_	_
85-7	15013-15019	global	_	_
85-8	15020-15032	connectivity	_	_
85-9	15032-15033	,	_	_
85-10	15034-15038	mean	_	_
85-11	15039-15051	connectivity	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	_
85-12	15052-15060	strength	_	_
85-13	15061-15063	of	_	_
85-14	15064-15067	all	_	_
85-15	15068-15081	non-homotopic	_	_
85-16	15082-15093	connections	_	_
85-17	15094-15095	(	_	_
85-18	15095-15098	i.e	_	_
85-19	15098-15099	.	_	_
85-20	15099-15100	,	_	_
85-21	15101-15104	all	_	_
85-22	15105-15121	intrahemispheric	_	_
85-23	15122-15125	and	_	_
85-24	15126-15137	heterotopic	_	_
85-25	15138-15154	interhemispheric	_	_
85-26	15155-15166	connections	_	_
85-27	15166-15167	)	_	_
85-28	15168-15171	was	_	_
85-29	15172-15180	included	_	_
85-30	15181-15183	as	_	_
85-31	15184-15185	a	_	_
85-32	15186-15198	fixed-effect	_	_
85-33	15199-15203	term	_	_
85-34	15204-15205	(	_	_
85-35	15205-15211	global	_	_
85-36	15212-15214	FC	_	_
85-37	15214-15215	)	_	_
85-38	15215-15216	.	_	_

86-1	15217-15223	Family	_	_
86-2	15224-15226	ID	_	_
86-3	15226-15227	,	_	_
86-4	15228-15236	encoding	_	_
86-5	15237-15240	the	_	_
86-6	15241-15249	subjects	_	_
86-7	15249-15250	'	_	_
86-8	15251-15259	pedigree	_	_
86-9	15260-15271	information	_	_
86-10	15271-15272	,	_	_
86-11	15273-15276	was	_	_
86-12	15277-15285	included	_	_
86-13	15286-15288	as	_	_
86-14	15289-15302	random-effect	_	_
86-15	15303-15307	term	_	_
86-16	15308-15310	to	_	_
86-17	15311-15318	control	_	_
86-18	15319-15322	for	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
86-19	15323-15329	family	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
86-20	15330-15334	ties	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
86-21	15335-15342	between	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
86-22	15343-15351	subjects	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
86-23	15352-15353	(	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
86-24	15353-15355	Eq	_	_
86-25	15355-15356	.	_	_
86-26	15357-15358	(	_	_
86-27	15358-15359	1	_	_
86-28	15359-15360	)	_	_
86-29	15360-15361	)	_	_
86-30	15361-15362	.	_	_

87-1	15363-15366	The	_	_
87-2	15367-15372	model	_	_
87-3	15373-15376	has	_	_
87-4	15377-15380	237	_	_
87-5	15381-15393	observations	_	_
87-6	15394-15395	(	_	_
87-7	15395-15401	number	_	_
87-8	15402-15404	of	_	_
87-9	15405-15413	subjects	_	_
87-10	15414-15418	with	_	_
87-11	15419-15427	complete	_	_
87-12	15428-15439	information	_	_
87-13	15439-15440	)	_	_
87-14	15440-15441	,	_	_
87-15	15442-15445	and	_	_
87-16	15446-15448	10	_	_
87-17	15449-15454	fixed	_	_
87-18	15455-15459	term	_	_
87-19	15460-15470	predictors	_	_
87-20	15471-15472	(	_	_
87-21	15472-15480	constant	_	_
87-22	15480-15481	,	_	_
87-23	15482-15495	group_sibling	_	_
87-24	15495-15496	,	_	_
87-25	15497-15510	group_patient	_	_
87-26	15510-15511	,	_	_
87-27	15512-15515	age	_	_
87-28	15515-15516	,	_	_
87-29	15517-15530	gender_female	_	_
87-30	15530-15531	,	_	_
87-31	15532-15547	handedness_left	_	_
87-32	15547-15548	,	_	_
87-33	15549-15565	handedness_mixed	_	_
87-34	15565-15566	,	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
87-35	15567-15574	scanner	_	_
87-36	15574-15575	_	_	_
87-37	15575-15577	#2	_	_
87-38	15577-15578	,	_	_
87-39	15579-15585	motion	_	_
87-40	15585-15586	,	_	_
87-41	15587-15593	global	_	_
87-42	15594-15596	FC	_	_
87-43	15596-15597	)	_	_
87-44	15597-15598	,	_	_
87-45	15599-15606	leaving	_	_
87-46	15606-15607	 	_	_
87-47	15607-15608	=	_	_
87-48	15608-15609	 	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
87-49	15609-15612	237	_	_
87-50	15612-15613	–	_	_
87-51	15613-15615	10	_	_
87-52	15615-15616	 	_	_
87-53	15616-15617	=	_	_
87-54	15617-15618	 	_	_
87-55	15618-15621	227	_	_
87-56	15622-15630	residual	_	_
87-57	15631-15638	degrees	_	_
87-58	15639-15641	of	_	_
87-59	15642-15649	freedom	_	_
87-60	15649-15650	.	_	_

88-1	15651-15659	Equation	_	_
88-2	15660-15661	1	_	_
88-3	15661-15662	:	_	_
88-4	15663-15666	For	_	_
88-5	15667-15678	hemispheric	_	_
88-6	15679-15693	specialization	_	_
88-7	15693-15694	,	_	_
88-8	15695-15700	group	_	_
88-9	15701-15707	status	_	_
88-10	15707-15708	,	_	_
88-11	15709-15712	age	_	_
88-12	15712-15713	,	_	_
88-13	15714-15717	sex	_	_
88-14	15717-15718	,	_	_
88-15	15719-15729	handedness	_	_
88-16	15729-15730	,	_	_
88-17	15731-15738	scanner	_	_
88-18	15739-15742	and	_	_
88-19	15743-15747	head	_	_
88-20	15748-15754	motion	_	_
88-21	15755-15759	were	_	_
88-22	15760-15765	again	_	_
88-23	15766-15774	included	_	_
88-24	15775-15777	as	_	_
88-25	15778-15790	fixed-effect	_	_
88-26	15791-15796	terms	_	_
88-27	15796-15797	.	_	_

89-1	15798-15810	Additionally	_	_
89-2	15810-15811	,	_	_
89-3	15812-15814	we	_	_
89-4	15815-15823	included	_	_
89-5	15824-15834	hemisphere	_	_
89-6	15835-15837	as	_	_
89-7	15838-15839	a	_	_
89-8	15840-15845	fixed	_	_
89-9	15846-15852	factor	_	_
89-10	15853-15855	to	_	_
89-11	15856-15863	examine	_	_
89-12	15864-15873	potential	_	_
89-13	15874-15885	differences	_	_
89-14	15886-15888	in	_	_
89-15	15889-15901	connectivity	_	_
89-16	15902-15910	patterns	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
89-17	15911-15918	between	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
89-18	15919-15922	the	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
89-19	15923-15926	two	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
89-20	15927-15938	hemispheres	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
89-21	15938-15939	.	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale

90-1	15940-15946	Random	_	_
90-2	15947-15953	effect	_	_
90-3	15954-15959	terms	_	_
90-4	15960-15967	include	_	_
90-5	15968-15974	family	_	_
90-6	15975-15977	ID	_	_
90-7	15978-15981	and	_	_
90-8	15982-15989	subject	_	_
90-9	15990-15992	ID	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
90-10	15993-15999	nested	_	_
90-11	16000-16006	within	_	_
90-12	16007-16013	family	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
90-13	16014-16016	ID	_	_
90-14	16016-16017	.	_	_

91-1	16018-16021	The	_	_
91-2	16022-16028	number	_	_
91-3	16029-16031	of	_	_
91-4	16032-16037	fixed	_	_
91-5	16038-16042	term	_	_
91-6	16043-16053	predictors	_	_
91-7	16054-16056	is	_	_
91-8	16057-16059	10	_	_
91-9	16060-16061	(	_	_
91-10	16061-16069	constant	_	_
91-11	16069-16070	,	_	_
91-12	16071-16084	group_sibling	_	_
91-13	16084-16085	,	_	_
91-14	16086-16099	group_patient	_	_
91-15	16099-16100	,	_	_
91-16	16101-16104	age	_	_
91-17	16104-16105	,	_	_
91-18	16106-16119	gender_female	_	_
91-19	16119-16120	,	_	_
91-20	16121-16136	handedness_left	_	_
91-21	16136-16137	,	_	_
91-22	16138-16154	handedness_mixed	_	_
91-23	16154-16155	,	_	_
91-24	16156-16163	scanner	_	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
91-25	16163-16164	_	_	_
91-26	16164-16166	#2	_	http://maven.renci.org/NeuroBridge/neurobridge#Pyromania
91-27	16166-16167	,	_	_
91-28	16168-16174	motion	_	_
91-29	16174-16175	,	_	_
91-30	16176-16189	hemisphere_RH	_	_
91-31	16189-16190	)	_	_
91-32	16190-16191	,	_	_
91-33	16192-16195	and	_	_
91-34	16196-16204	residual	_	_
91-35	16205-16212	degrees	_	_
91-36	16213-16215	of	_	_
91-37	16216-16223	freedom	_	_
91-38	16224-16226	is	_	_
91-39	16227-16230	237	_	_
91-40	16230-16231	 	_	_
91-41	16231-16232	×	_	_
91-42	16232-16233	 	_	_
91-43	16233-16234	2	_	_
91-44	16235-16236	(	_	_
91-45	16236-16246	hemisphere	_	_
91-46	16246-16247	)	_	_
91-47	16248-16249	–	_	_
91-48	16250-16252	10	_	_
91-49	16252-16253	 	_	_
91-50	16253-16254	=	_	_
91-51	16254-16255	 	_	_
91-52	16255-16258	464	_	_
91-53	16258-16259	.	_	_

92-1	16260-16268	Equation	_	_
92-2	16269-16270	2	_	_
92-3	16270-16271	:	_	_
92-4	16272-16284	Linear-mixed	_	_
92-5	16285-16292	effects	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
92-6	16293-16301	analysis	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
92-7	16302-16305	was	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
92-8	16306-16311	first	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
92-9	16312-16319	applied	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
92-10	16320-16322	to	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
92-11	16323-16330	overall	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
92-12	16331-16347	interhemispheric	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
92-13	16348-16360	connectivity	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
92-14	16361-16364	and	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
92-15	16365-16376	hemispheric	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
92-16	16377-16391	specialization	_	_
92-17	16392-16393	(	_	_
92-18	16393-16394	p	_	_
92-19	16394-16395	 	_	_
92-20	16395-16396	<	_	_
92-21	16396-16397	 	_	_
92-22	16397-16400	.05	_	_
92-23	16400-16401	)	_	_
92-24	16401-16402	,	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
92-25	16403-16406	and	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
92-26	16407-16411	then	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
92-27	16412-16414	to	_	_
92-28	16415-16419	each	_	_
92-29	16420-16422	of	_	_
92-30	16423-16425	56	_	_
92-31	16426-16434	regional	_	_
92-32	16435-16447	measurements	_	_
92-33	16447-16448	,	_	_
92-34	16449-16460	controlling	_	_
92-35	16461-16464	for	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
92-36	16465-16473	multiple	_	_
92-37	16474-16485	comparisons	_	_
92-38	16486-16487	(	_	_
92-39	16487-16488	p	_	_
92-40	16488-16489	 	_	_
92-41	16489-16490	<	_	_
92-42	16490-16491	 	_	_
92-43	16491-16494	.05	_	_
92-44	16494-16495	,	_	_
92-45	16496-16506	Bonferroni	_	_
92-46	16507-16516	corrected	_	_
92-47	16516-16517	)	_	http://maven.renci.org/NeuroBridge/neurobridge#DissociativeDrugHarmfulUse
92-48	16517-16518	.	_	http://maven.renci.org/NeuroBridge/neurobridge#DissociativeDrugHarmfulUse

93-1	16519-16526	Overall	_	_
93-2	16527-16530	and	_	_
93-3	16531-16539	regional	_	_
93-4	16540-16552	measurements	_	_
93-5	16553-16557	with	_	_
93-6	16558-16569	significant	_	_
93-7	16570-16575	group	_	_
93-8	16576-16583	effects	_	_
93-9	16584-16588	were	_	_
93-10	16589-16598	subjected	_	_
93-11	16599-16601	to	_	_
93-12	16602-16610	post-hoc	_	_
93-13	16611-16620	bivariate	_	_
93-14	16621-16632	comparisons	_	_
93-15	16633-16640	between	_	_
93-16	16641-16645	each	_	_
93-17	16646-16650	pair	_	_
93-18	16651-16653	of	_	_
93-19	16654-16661	subject	_	_
93-20	16662-16668	groups	_	_
93-21	16669-16670	(	_	_
93-22	16670-16671	p	_	_
93-23	16671-16672	 	_	_
93-24	16672-16673	<	_	_
93-25	16673-16674	 	_	_
93-26	16674-16677	.05	_	_
93-27	16677-16678	)	_	_
93-28	16678-16679	.	_	_

94-1	16680-16692	Relationship	_	_
94-2	16693-16700	between	_	_
94-3	16701-16717	interhemispheric	_	_
94-4	16718-16730	connectivity	_	_
94-5	16731-16734	and	_	_
94-6	16735-16746	hemispheric	_	_
94-7	16747-16761	specialization	_	_
94-8	16762-16764	To	_	_
94-9	16765-16769	test	_	_
94-10	16770-16777	whether	_	_
94-11	16778-16799	schizophrenia-related	_	_
94-12	16800-16807	changes	_	_
94-13	16808-16810	in	_	_
94-14	16811-16827	interhemispheric	_	_
94-15	16828-16840	connectivity	_	_
94-16	16841-16848	co-vary	_	_
94-17	16849-16853	with	_	_
94-18	16854-16865	alterations	_	_
94-19	16866-16868	in	_	_
94-20	16869-16880	hemispheric	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
94-21	16881-16895	specialization	_	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
94-22	16895-16896	,	_	_
94-23	16897-16899	we	_	_
94-24	16900-16910	calculated	_	_
94-25	16911-16914	the	_	_
94-26	16915-16919	mean	_	_
94-27	16920-16930	difference	_	_
94-28	16931-16938	between	_	_
94-29	16939-16947	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_
94-30	16948-16951	and	_	_
94-31	16952-16960	patients	_	_
94-32	16961-16963	on	_	_
94-33	16964-16968	both	_	_
94-34	16969-16981	measurements	_	_
94-35	16982-16985	for	_	_
94-36	16986-16990	each	_	_
94-37	16991-16996	brain	_	_
94-38	16997-17003	region	_	_
94-39	17003-17004	.	_	_

95-1	17005-17014	Pearson's	_	_
95-2	17015-17026	correlation	_	_
95-3	17027-17035	analysis	_	_
95-4	17036-17039	was	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	_
95-5	17040-17049	performed	_	_
95-6	17050-17052	on	_	_
95-7	17053-17070	group-differences	_	_
95-8	17071-17073	of	_	_
95-9	17074-17090	interhemispheric	_	_
95-10	17091-17103	connectivity	_	_
95-11	17104-17107	and	_	_
95-12	17108-17119	hemispheric	_	_
95-13	17120-17134	specialization	_	_
95-14	17135-17141	across	_	_
95-15	17142-17149	regions	_	_
95-16	17150-17151	(	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
95-17	17151-17152	p	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
95-18	17152-17153	 	_	_
95-19	17153-17154	<	_	_
95-20	17154-17155	 	_	_
95-21	17155-17158	.05	_	_
95-22	17158-17159	)	_	_
95-23	17159-17160	.	_	_

96-1	17161-17164	The	_	_
96-2	17165-17169	same	_	_
96-3	17170-17178	analysis	_	_
96-4	17179-17182	was	_	_
96-5	17183-17192	performed	_	_
96-6	17193-17196	for	_	_
96-7	17197-17205	siblings	_	_
96-8	17206-17208	as	_	_
96-9	17209-17217	compared	_	_
96-10	17218-17220	to	_	_
96-11	17221-17229	patients	_	_
96-12	17229-17230	,	_	_
96-13	17231-17234	and	_	_
96-14	17235-17238	for	_	_
96-15	17239-17247	controls	_	_
96-16	17248-17256	compared	_	_
96-17	17257-17259	to	_	_
96-18	17260-17268	siblings	_	_
96-19	17268-17269	.	_	_

97-1	17270-17281	Correlation	_	_
97-2	17282-17289	between	_	_
97-3	17290-17302	connectivity	_	_
97-4	17303-17313	alteration	_	_
97-5	17314-17317	and	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
97-6	17318-17326	clinical	_	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
97-7	17327-17334	factors	_	_
97-8	17335-17337	To	_	_
97-9	17338-17345	examine	_	_
97-10	17346-17349	the	_	_
97-11	17350-17359	potential	_	_
97-12	17360-17368	clinical	_	_
97-13	17369-17378	relevance	_	_
97-14	17379-17381	of	_	_
97-15	17382-17394	connectivity	_	_
97-16	17395-17402	changes	_	_
97-17	17403-17405	in	_	_
97-18	17406-17414	patients	_	_
97-19	17414-17415	,	_	_
97-20	17416-17419	the	_	_
97-21	17420-17425	level	_	_
97-22	17426-17428	of	_	_
97-23	17429-17445	interhemispheric	_	_
97-24	17446-17458	connectivity	_	_
97-25	17459-17462	and	_	_
97-26	17463-17474	hemispheric	_	_
97-27	17475-17489	specialization	_	_
97-28	17490-17494	were	_	_
97-29	17495-17505	correlated	_	_
97-30	17506-17510	with	_	_
97-31	17511-17518	illness	_	_
97-32	17519-17527	duration	_	_
97-33	17528-17531	and	_	_
97-34	17532-17537	PANSS	_	_
97-35	17538-17543	total	_	_
97-36	17544-17550	scores	_	_
97-37	17551-17553	in	_	_
97-38	17554-17562	patients	_	_
97-39	17563-17564	(	_	_
97-40	17564-17565	p	_	_
97-41	17565-17566	 	_	_
97-42	17566-17567	<	_	_
97-43	17567-17568	 	_	_
97-44	17568-17571	.05	_	_
97-45	17571-17572	)	_	_
97-46	17572-17573	.	_	_

98-1	17574-17582	Moreover	_	_
98-2	17582-17583	,	_	_
98-3	17584-17597	antipsychotic	_	_
98-4	17598-17608	medication	_	_
98-5	17609-17612	was	_	_
98-6	17613-17621	examined	_	_
98-7	17622-17624	as	_	_
98-8	17625-17626	a	_	_
98-9	17627-17636	potential	_	_
98-10	17637-17647	confounder	_	_
98-11	17648-17650	of	_	_
98-12	17651-17661	functional	_	_
98-13	17662-17674	connectivity	_	_
98-14	17675-17687	measurements	_	_
98-15	17688-17690	by	_	_
98-16	17691-17702	correlating	_	_
98-17	17703-17708	daily	_	_
98-18	17709-17719	medication	_	_
98-19	17720-17722	in	_	_
98-20	17723-17737	chlorpromazine	_	_
98-21	17738-17748	equivalent	_	_
98-22	17749-17753	dose	_	_
98-23	17754-17758	with	_	_
98-24	17759-17775	interhemispheric	_	_
98-25	17776-17788	connectivity	_	_
98-26	17789-17792	and	_	_
98-27	17793-17804	hemispheric	_	_
98-28	17805-17819	specialization	_	_
98-29	17819-17820	.	_	_






































































































